NCT03466749Unknown不适用
A Real-world Study in China: the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment
Xijing Hospital1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2018年2月22日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 600
- 试验地点
- 1
- 主要终点
- TVF of 12 months after surgery
研究概览
简要总结
The aim of this Real-world study in China is evaluating the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary de-novo lesions(target vessel diameter:2.5mm-4.0mm)Treatment. And the primary point of this study is the target lesion failure of 12 months after surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 78 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-78 years of age, male or non-pregnant female;
- •patients with asymptomatic or symptomatic myocardial ischemia, stable or unstable angina pectoris, myocardial infarction with a course of more than two weeks, and patients with indications for percutaneous coronary intervention;
- •the target lesions were primary, in situ coronary artery stenosis, located on one or two different coronary artery vessels, the number of target lesions on each coronary artery was not more than one;
- •the length of the target lesion ≤ 26mm (visual), which can be covered by a single drug balloon (it is suggested that the balloon should cover at least 4mm healthy partition, 2 mm at each end; The reference diameter of target vessel was 2.5mm-4.0mm (visual);
- •the stenosis degree of the target lesion was ≥ 70%;
- •left ventricular ejection fraction ≥ 45%.
- •patients who can understand the purpose of the trial, voluntarily participate and sign informed consent, and are willing to follow up the study.
排除标准
- •Related to patients:
- •patients with myocardial infarction within two weeks;
- •pregnant or lactating women;
- •cardiogenic shock, acute infection, known bleeding or coagulation disorder, or active digestive tract; Patients with history of hemorrhage or ulcer, cerebral hemorrhage or subarachnoid hemorrhage, stroke within half a year;
- •patients with a life expectancy less than one year or with difficulties in clinical follow-up;
- •patients who had a history of PTCA or had other operations scheduled during the follow-up period of one year;
- •patients who are participating in any other clinical study and who have not reached the main end point of the study;
- •present or previous history of severe liver disease, and / or renal impairment: serum creatinine > 2.0 mg / dl( 176.8 umol / L) or undergoing hemodialysis therapy. Therefore, it does not meet the requirements of angiography;
- •patients with left ventricular ejection fraction below 45%;
- •for other reasons, the researchers did not think it was appropriate for a patient to be selected.
- •Related to lesions:
- •left main lesion and the bifurcation with side branch >2.5 mm;
- •the location of the lesion was less than 10 mm at the proximal end of the anterior descending branch, 5 mm in the circumflex branch and 5 mm in the proximal end of the right coronary artery.
- •severe calcification and twisted lesions which can not be successfully predilated, are not suitable for drug balloon delivery and expansion.
- •lesion length ≥ 26 mm;
- •evidence of severe thrombosis in target vessels before intervention;
- •lesions that cannot be treated with PTCA or other interventional techniques;
- •after predilation of the target lesion, residual stenosis ≥ 30% or TIMI blood flow < 3, and / or obvious flow limiting dissection.
- •Exclusion criteria related to drugs:
- •patients with bleeding constitution, anticoagulant or antiplatelet drugs;
- •patients who cannot tolerate aspirin and / or clopidogrel or who have a history of neutropenia or thrombocytopenia or who have too severe liver failure to receive clopidogrel;
- •patients known to be intolerant or allergic to heparin, contrast agents, paclitaxel, iopramide, rapamycin, polylactic acid-glycolic acid polymer, stainless steel, etc.
- •leukopenia (leukocyte count < 3 × 109 / L and the course > 3 days) or neutropenia ANC < 1000 neutrophil / mm3 and the course> 3 days). Or patients had a history of thrombocytopenia (< 100,000 platelets / mm3;
- •patients with a history of peptic ulcer or gastrointestinal bleeding in the past 6 months.
研究组 & 干预措施
Intervention group
Experimental
Paclitaxel Eluting Balloon Catheter treatment
干预措施: Paclitaxel Eluting Balloon Catheter (Device)
结局指标
主要结局
TVF of 12 months after surgery
时间窗: 12 months after surgery
target vessel failure of 12 months after surgery
次要结局
未报告次要终点
研究者
Ling Tao
Doctor
Xijing Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 DiabetesDiabetesNCT06553248Gan and Lee Pharmaceuticals, USA36
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy SubjectsHealthyNCT06423261Zhejiang Echon Biopharm Limited100
已完成
1 期
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT05596747Eli Lilly and Company31
进行中（未招募）
不适用
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast CancerBreast CancerNCT05594082Fudan University150
已完成
2 期
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With AchondroplasiaAchondroplasiaNCT05246033Visen Pharmaceuticals (Shanghai) Co., Ltd.24